文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

优化治疗指数:序贯动脉-静脉PRRT联合个体化体积调整剂量

Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.
PubMed 文献 · J Nucl Med · 2026-09-24

该前瞻性临床试验纳入10例进展性、不可切除、肝转移为主的胃肠胰NET患者,采用2周期动脉后2周期静脉的177Lu-DOTATATE方案。动脉给药可行率100%,肝转移灶吸收剂量较静脉高3倍以上,中位摄取增86%,3个月部分缓解率67%、6个月87%,总体安全。

要点

  • 动脉给药可行率100%,肝转移灶吸收剂量较静脉高3倍以上
  • 68Ga-DOTATATE PET示动脉给药后肝病灶中位摄取增86%
  • 部分缓解率3个月67%、6个月87%,仅1例严重不良事件

核心结论

  • 序贯动脉后静脉177Lu-DOTATATE对肝转移为主NET可行且安全,个体化体积调整提高肝转移摄取与吸收剂量,客观缓解率高并维持全身覆盖。

研究设计与样本

  • 前瞻性临床试验纳入10例连续成人进展性、不可切除、肝转移为主、生长抑素受体阳性的胃肠胰NET患者。
  • 方案为每2月1周期共4周期177Lu-DOTATATE,先2周期动脉后2周期静脉给药。
  • 动脉给药经血管造影引导选择性肝动脉插管,按体积调整活性以最大化靶向递送。

主要发现

  • 动脉给药操作可行率100%,工作人员与患者辐射暴露在监管限值内,无污染事件。
  • 剂量学分析示动脉给药(第1周期)肝转移灶吸收剂量较静脉(第3周期)高3倍以上,但 interim 缓解可能起作用。
  • 68Ga-DOTATATE PET示动脉给药后肝病灶中位摄取增86%。
  • 方案总体耐受良好,仅报告1例严重不良事件(低位食管撕裂),未归因于给药途径。
  • 按RECIST与体积标准,治疗结束后3个月首次随访部分缓解率67%,6个月第二次随访升至87%。

关键数值与推荐

  • 动脉给药(第1周期)肝转移灶吸收剂量较静脉(第3周期)高3倍以上。
  • 68Ga-DOTATATE PET示动脉给药后肝病灶中位摄取增86%。
  • 部分缓解率:治疗结束后3个月67%,6个月87%(RECIST与体积标准)。
  • 动脉给药操作可行率100%,仅1例严重不良事件(低位食管撕裂)。

临床怎么用

  • 对肝转移为主、生长抑素受体阳性的进展性胃肠胰NET,可考虑序贯动脉后静脉177Lu-DOTATATE以强化肝病灶剂量。
  • 动脉给药需血管造影引导选择性肝动脉插管并按体积调整活性,同时监测辐射防护与剂量学。
  • 疗效评估可结合RECIST与体积标准,随访中关注客观缓解动态变化。

局限性

  • 样本量仅10例,为初步可行性、耐受性与疗效探索。
  • 动脉与静脉剂量比较受 interim 缓解可能影响,非完全随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with well-differentiated neuroendocrine tumors (NETs) frequently present with liver-dominant metastases, which significantly impact prognosis and limit curative options. Although standard intravenous peptide receptor radionuclide therapy with 177Lu-DOTATATE is effective, strategies to intensify the radiation dose to hepatic lesions are needed to improve outcomes. This prospective clinical trial investigated the feasibility, tolerability, and preliminary efficacy of a personalized treatment schedule combining intraarterial and intravenous administrations of 177Lu-DOTATATE. Methods: Ten consecutive adults with progressive, nonresectable, liver-dominant metastatic gastroenteropancreatic NETs expressing somatostatin receptors were enrolled. The treatment protocol comprised 4 cycles of 177Lu-DOTATATE administered every 2 mo (2 initial intraarterial cycles followed by 2 intravenous cycles). Intraarterial administration involved angiographically guided, selective catheterization of the hepatic arteries with volumetrically adjusted activity to maximize targeted delivery. Safety monitoring, radiation protection, and dosimetry comparisons between intraarterial and intravenous routes were performed. Results: The intraarterial administration procedure was feasible in 100% of patients. Radiation exposure to staff and patients remained within regulatory limits, with no contamination events. Dosimetry analysis indicated that intraarterial administration (cycle 1) delivered a greater than 3-fold higher radiation dose to liver metastases compared with the intravenous route (cycle 3), although interim response may have played a role. Furthermore, 68Ga-DOTATATE PET imaging revealed an 86% increase in median liver lesion uptake with intraarterial administration. The regimen was generally well-tolerated, with only 1 severe adverse event reported (low esophageal tear), which was not attributed to the administration route. Efficacy analysis showed partial response rates in 67% of patients at the first follow-up 3 mo after treatment completion, improving to 87% at the second follow-up (6 mo) in accordance with RECIST and volumetric criteria. Conclusion: The sequential administration of intraarterial followed by intravenous 177Lu-DOTATATE is a feasible and safe therapeutic strategy for liver-dominant metastatic NETs. The use of a personalized, volumetric-based approach provided higher uptake and absorbed doses in hepatic metastases, with high objective response rates and effectively maintained systemic coverage.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bodei L, Ziv E, Mauguen A, et al. Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing. J Nucl Med. 2026. PMID: 42785954. doi:10.2967/jnumed.126.272710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。